PFE and MRK ae both struggling today
Vaxcyte Inc (NASDAQ:PCVX) stock is surging today, after the biotechnology company announced positive study results for its drug designed to prevent invasive pneumococcal disease in adults aged 50 or older. Competitors Pfizer Inc (NYSE:PFE) and Merck & Co Inc (NYSE:MRK) are moving lower amid those headlines, however. Below, let’s dig into how these stocks have fared on the charts lately.
PCVX was last seen up 38.7% to trade at $111.98, and earlier notched a fresh all-time high of $119.27. The equity found recent support from the 60-day moving average, and is today pacing for its third-straight daily gain and best day since October 2022 as it blasts through resistance at the $81 level. So far this year, the stock added 76.9%.
Last seen down 1.9% to trade at $28.45, PFE has been struggling with pressure at the $29 region since falling from its July 30 peak of $31.54. Shares are also testing support at their 100-day moving average, which contained a mid-August pullback. In the last 12 months, the security shed over 20%.
MRK is down 1.3% to trade at $116.94 at last glance, on track to snap a four-day win streak. A rally off its lowest level since January came short of the $120 level, and the equity has been trading firmly below the 40-day moving average since late June. For 2024, Merck stock still sports a slim 7.2% lead.